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Abstract
Background: Elevated platelet count is associated with risk of venous thromboembolism in cancer patients initiating
chemotherapy. It is not known whether this risk by platelet count is causal or merely reflects the malignant disease. We
investigated whether pre-cancer platelet count alone or together with high leukocyte count was associated with risk of
venous thromboembolism in subjects who did and did not develop cancer during follow-up in a population-based cohort
study.
Methods: Platelet count and other baseline characteristics were measured in 25160 initially cancer-free subjects who
participated in the Tromsø Study in 1994–1995. Incident cancer and symptomatic venous thromboembolism events were
registered up to December 31st, 2009. Multivariable Cox regression models were used to calculate hazard ratio for venous
thromboembolism across categories of platelet count (,40th, 40–80th, and .80th percentile) with 95% confidence interval.
Results: During follow-up, 2082 subjects were diagnosed with cancer. Platelet count was measured on average 8.3 years
before the cancer diagnosis. There were 129 venous thromboembolism events in the cancer cohort (13.5 per 1000 person-
years) and 377 in the non-cancer cohort (1.2 per 1000 person-years). In cancer patients, pre-cancer platelet count above the
80th percentile ($2956109/L) was associated with a 2-fold higher risk of venous thromboembolism (Hazard ratio: 1.98, 95%
confidence interval 1.21–3.23) compared to platelet count below the 40th percentile (,2356109/L). Concomitant high
platelet and leukocyte counts showed a synergistic effect on the VTE risk. In cancer-free subjects, no association was found.
Comment: In conclusion, pre-cancer platelet count was associated with risk of symptomatic venous thromboembolism in
cancer patients, but not in cancer-free subjects. Our findings suggest that platelet count and platelet-leukocyte interactions
may play a role in the pathogenesis of cancer-related venous thromboembolism.
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Introduction
The association between malignant disease and venous throm-
boembolism (VTE) was described by Armand Trousseau in the
1860s [1]. VTE, which includes deep venous thrombosis and
pulmonary embolism, is still a frequent complication and a leading
cause of death in cancer patients [2]. Overall, cancer is associated
with 20–30% of the incident VTE cases [2]. A recent meta-
analysis reported that the annual incidence of VTE in patients
with cancer varied between 0.5% and 20%, depending on cancer
sites, stage, cancer treatment and time since diagnosis [3].
Furthermore, cancer patients with VTE have more bleeding
complications on anticoagulation treatment [4], higher rates of
recurrent VTE [4] and more frequent and prolonged hospital
stays [5] compared to VTE patients without malignancy.
Platelets are essential in hemostasis and the formation of both
arterial [6] and venous thrombosis [7]._ENREF_12 Cancer
represents a hypercoagulable state where activated platelets
promote angiogenesis, tumor progression and metastasis [8,9].
An elevated platelet count is a common finding and a strong
predictor of decreased survival in cancer patients [8,10]. Platelet
count is not associated with future VTE in population-based
cohorts [11–13], but studies of cancer patients initiating chemo-
therapy have demonstrated that a high platelet count predicts
increased risk of VTE [14–16]. Since an elevated platelet count in
patients with active cancer might merely reflect an aggressive
disease state with a higher thrombotic potential, it is not known
whether there is a causal relationship between platelet count and
VTE risk in cancer patients.
To address this question, we used data from the Tromsø Study,
a large population-based cohort study, to investigate whether pre-
cancer platelet count was associated with increased risk of
symptomatic VTE in subjects who developed cancer during
follow-up and in subjects who remained cancer-free. Recently,
high leukocyte count measured prior to cancer development was
shown to predict VTE in cancer patients [17]. Together with a
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biological rationale for platelet-leukocyte interactions in venous
thrombosis [7,18], this encouraged us to examine the joint effect of
platelet and leukocyte counts on future risk of VTE.
Methods
Ethics statement
The study was approved by the Regional Committee for
Medical and Health Research Ethics in Northern Norway, and the
participants gave their informed written consent.
Study population
Participants were recruited from the fourth survey of the
Tromsø Study, a single-center, prospective, population-based
study which was carried out in 1994–1995. All inhabitants aged
over 24 years living in the municipality of Tromsø were invited
and 27 158 participated (77% of the eligible population). Subjects
who did not consent to medical research (n = 202), who were no
longer registered as inhabitants of the municipality of Tromsø
(n = 44) at the time of enrollment, with a previous diagnosis of
cancer (n = 764) or VTE (n = 53), or with missing values for
platelet count (n = 808) were excluded. In order to minimize the
possibility that platelet count at baseline could be confounded by
occult malignancy, subjects with a cancer diagnosis during the first
year after enrollment were excluded from the analyses (n = 127).
Accordingly, the total study population consisted of 25 160
subjects. Incident cancer diagnosis and VTE events among the
study participants were recorded from the date of enrollment
(1994–95) to the end of follow up, December 31st, 2009.
Baseline measurements
Baseline information in the Tromsø Study was obtained by
physical examination, blood samples and self-administered ques-
tionnaires. The blood samples were collected from the antecubital
vein and analyzed at the department of Clinical Chemistry,
University Hospital of North Norway. For measurement of platelet
counts, 5 ml of blood was drawn into a vacationer tube containing
EDTA as an anticoagulant (K3- EDTA 40 mL, 0.37 mol/L per
tube), and analyzed within 12 hours by an automated blood cell
counter (Coulter CounterH, Coulter Electronics, Luton, UK).
Body height and weight were measured in subjects wearing light
clothing and no shoes. Body mass index was calculated as weight
in kilograms, divided by the square of the height in meters (kg/m2).
Information about current daily smoking status, history of
cardiovascular disease (myocardial infarction, angina or stroke),
diabetes, higher education (university/college level) and physical
activity (exercise that caused sweating or breathlessness $ one
hour per week) were obtained from the self-administered
questionnaires.
Identification and validation of cancer- and venous
thromboembolism diagnosis
Information about the date of cancer diagnosis, location of the
disease (ICD-7-codes 140-205) and cancer stage (localized disease
or presence of regional/distant metastasis) was obtained from
linkage to the Cancer Registry of Norway. Subjects with non-
melanoma skin cancers (ICD 191.0–191.9) were classified as
cancer-free. The Cancer Registry of Norway is a complete and
valid registry; a recent evaluation of data quality displayed 98.8%
completeness, of which 94% had organ specific morphology [19].
First life time VTE events during follow up were identified by
searching the hospital discharge diagnosis registry, the radiology
procedure registry and the autopsy registry at the University
Hospital of North Norway, previously described by Braekkan et al
[13]. The University Hospital of North Norway is the only hospital
serving the municipality of Tromsø, and all relevant diagnostic
procedures and hospital care are provided here. The discharge
diagnosis registry includes both outpatient clinic visits and
hospitalizations. The medical record for each potential case of
VTE was reviewed by trained personnel, and a VTE event was
considered verified and recorded when presence of clinical signs
and symptoms of deep venous thrombosis or pulmonary embolism
were combined with objective confirmation tests (compression
ultrasonography, venography, spiral computed tomography,
perfusion-ventilation scan, pulmonary angiography, autopsy),
and resulted in a VTE diagnosis that required treatment. VTE
cases from the autopsy registry were recorded when the death
certificate indicated VTE as cause of death or a significant
condition associated with death.
A VTE event was classified as cancer-related if it occurred
within one year prior to the cancer diagnosis (occult cancer) or
after (overt cancer). Provoking factors (other than cancer) at the
time of VTE diagnosis were recorded for all VTE events. These
included surgery or trauma within the previous 8 weeks, acute
medical conditions (acute myocardial infarction, ischemic stroke or
major infectious disease), immobilization (bed rest .3 days, wheel
chair use, long haul travel exceeding 4 hours in the past 14 days)
or other provoking factors described by the physician in the
medical record (e.g. intravascular catheter).
Statistical analyses
For each participant, person-years of follow-up were accrued
from the date of inclusion in 1994–95 and to the date of a VTE
event, migration, death or to the end of the study period
(December 31st, 2009), whichever came first. Subjects who
developed cancer during follow-up contributed with person-years
in the non-cancer cohort from the baseline inclusion date until the
date one year prior to their cancer diagnosis. Thereafter they
contributed with person-years in the cancer cohort (from the date
one year prior to cancer diagnosis) to the end of follow-up. The
switch of cancer status one year prior to cancer diagnosis was
chosen in order to include VTEs that occurred in the presence of
occult cancer as cancer-related VTEs.
The STATA nptrend command, a nonparametric test for trend
across ordered groups, was used to assess p-values for linear trends
in distribution of baseline variables (Table 1) and cancer diagnoses
(Table 2) across categories of platelet count. Multivariable Cox
proportional hazards regression models were used to calculate
hazard ratios (HRs) with 95% confidence intervals (CIs) for VTE
across categories of platelet count (,40th, 40–80th, and .80th
percentiles), in the cancer and non-cancer cohorts respectively.
The lower 40th percentile was used as reference group. The first
regression model (Model 1) was adjusted for age and sex, whereas
the second model (Model 2) included age, sex, body mass index,
smoking, mean platelet volume and leukocyte count as covariates.
Among the baseline variables, only age, body mass index and
leukocyte count were significantly associated with VTE in our
analyses. However, sex, smoking and mean platelet volume were
also included as covariates because of their highly significant
trends across platelet count categories combined with their
possible association with VTE [13,20,21]. The third Cox model
(Model 3) was performed in cancer subjects only, and was an
extended version of Model 2 which additionally included the
variable cancer stage (localized or disseminated disease). Finally,
the association between platelet count (continuous variable) and
risk of VTE in subjects with and without cancer was visualized by
generalized additive regression plots. Platelet count (log trans-
formed) in these plots was modeled with a 4-degrees of freedom
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smoothing spline fit in Cox proportional hazard models including
the variables in Model 2 as described above.
Statistical interactions between platelet count and the other
variables in the models were tested by including cross-product
terms in the proportional hazard models, and no interactions were
found. However, a statistical interaction between platelet count
and cancer was confirmed, which justified separate analyses for
cancer and non-cancer subjects. The proportional hazards
assumption was confirmed by an evaluation of the parallelism
between the curves of the log-log survivor function.
For further elucidation of causality, we additionally investigated
whether a high platelet count in itself was associated with cancer,
using a Cox-regression model where person-years were counted
from baseline inclusion until the date of cancer diagnosis (event),
death (censored) or end of study (December 31, 2009), whichever
came first.
Furthermore, we assessed the joint effect of platelet and
leukocyte counts on VTE-risk. Four categories were generated
by combining platelet count with leukocyte count: low-low:
platelet count ,2956109/L and leukocyte count ,8.66109/L,
low-high: platelet count ,2956109/L and leukocyte count
$8.66109/L, high-low: platelet count$2956109/L and leukocyte
count ,8.66109/L and high-high: platelet count$2956109/L
and leukocyte count $8.66109/L. The low-low category was used
as reference group in the Cox models. The simple regression
model included sex and age, while the two more complex analyses
were adjusted for age, sex, smoking, body mass index, mean
platelet volume and stage. Rothman synergy index [22] was used
to determine whether the joint effect from high leukocyte count
and high platelet count on VTE risk exceeded the sum of the effect
from each factor alone. Synergy index = (RRab -1)/(RRa + RRb -
2). RRab is the relative risk of the joint exposure group; RRa and
RRb are relative risk for the exposure of high leukocyte and high
platelet count, respectively. A value above 1.0 suggests that effect
of the joint exposures of two risk factors is greater than the sum of
the separate effects. The proportion attributable to the interaction
was calculated (AP = (RRab-RRa-RRb+1)/RRab) to demonstrate
the proportion of cases that could be explained by the interaction.
Statistical analyses were carried out using SPSS (version 19.0;
IBM SPSS Statistics), STATA (version 13; Stata Corporation,
College Station, TX, USA) and R (version 2.15.1 for windows).
Results
In total, 2082 participants developed cancer during follow-up.
Baseline characteristics in the cancer and the non-cancer cohort
across categories of platelet count are presented in Table 1. The
Table 1. Baseline characteristics across categories of platelet count in subjects who developed cancer and subjects who remained
cancer-free during follow up; The Tromsø Study 1994–2009.
Categories of platelet count (109/L) P for trend
,235 235–294 $295
Cancer
Subjects, n 906 773 403
Age (years), mean 61 SD 59.2612.9 56.7612.8 54.8612.5 ,0.001
Sex (females), % (n) 41.5 (376) 53.0 (410) 56.8 (229) ,0.001
BMI, mean 61 SD 26.064.0 25.663.9 25.364.3 ,0.001
Daily smoking, % (n) 37.5 (339) 41.4 (320) 49.1 (198) ,0.001
Physical activity*, % (n) 21.8 (195) 23.6 (181) 21.5 (86) 0.9
Self-reported DM, % (n) 4.4 (40) 2.9 (22) 0.7 (3) ,0.001
Self-reported CVD, % (n) 13.7 (124) 7.8 (60) 10.9 (44) 0.02
Higher education, % (n) 21.2 (190) 19.9 (154) 15.7 (63) 0.03
Leuk count, mean 61 SD 6.762.5 7.361.9 8.162.1 ,0.001
MPV, mean 61 SD 9.261.0 8.660.7 8.260.7 ,0.001
Non-cancer
Subjects (n) 9055 9263 4760
Age (years), mean 61 SD 46.6615.3 44.9614.1 43.6613.3 ,0.001
Sex (female), % (n) 44.7 (4044) 54.7 (5065) 64.2 (3058) ,0.001
BMI, mean 61 SD 25.063.6 25.163.8 25.364.1 0.001
Daily smoking, % (n) 33.2 (3004) 38.0 (3515) 42.0 (1994) ,0.001
Physical activity*, % (n) 32.8 (2949) 32.6 (3001) 27.2 (1286) ,0.001
Self-reported DM, % (n) 1.9 (170) 1.4 (129) 1.3 (62) 0.004
Self-reported CVD, % (n) 7.4 (669) 5.2 (479) 4.0 (190) ,0.001
Higher education, % (n) 33.3 (3009) 30.7 (2829) 27.2 (1293) ,0.001
Leuk count, mean 61 SD 6.561.7 7.261.9 8.062.1 ,0.001
MPV, mean 61 SD 9.161.0 8.660.8 8.260.7 ,0.001
*Physical activity $ une hour per week of activity that caused sweating or breathlessness.
Abbreviations: SD; standard deviation, BMI; Body mass index (kg/m2), DM; Diabetes mellitus, CVD; Cardiovascular disease, Leuk count; Leukocyte count (109/L), MPV;
Mean platelet volume (fL).
doi:10.1371/journal.pone.0092011.t001
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mean age in the cancer cohort (57 years) was higher than in the
non-cancer cohort (45 years), and declined across categories of
platelet count in both cohorts. Body mass index was slightly higher
with higher platelet count only in the cancer-free cohort. The
leukocyte count and the proportion of females and current
smokers increased across platelet categories in both cohorts.
In subjects who developed cancer during follow-up, the mean
time from baseline to cancer diagnosis was 8.3 years. Platelet count
was not associated with risk of cancer (HR Model 2: 1.03, 95% CI
0.89–1.18) (Table S1). Cancer characteristics by increasing platelet
count at the time of cancer diagnosis are shown in Table 2. The
proportion of subjects with localized disease decreased across
categories of platelet count. There were more subjects with
prostate cancer in the lowest category of platelet count, which may
be due to the higher age in this category. The proportion of
subjects with lung cancer increased across categories, which was
probably related to the effect of smoking on platelet count. The
proportion of subjects with pancreas cancer decreased across
categories.
The characteristics of cancer patients and non-cancer patients
at the time of the symptomatic VTE event are presented in Table
S2. There were 129 incident VTE events in the cancer cohort and
377 in the non-cancer cohort. In the cancer cohort, 19% of the
subjects had VTE within one year prior to the cancer diagnosis,
and 81% after. The mean age, the gender distribution, and the
total proportion of provoking factors were essentially similar in the
two cohorts.
Incidence rates and hazard ratios for VTE across categories of
platelet count are shown in Table 3. The mean observational time
in the cancer-cohort was 4.6 years versus 12.3 years in the non-
cancer cohort. The overall crude incidence of VTE was 13.5 per
1000 person-years in the cancer-cohort and 1.2 per 1000 person
years in the non-cancer cohort. In cancer patients, a 2-fold
increased risk of VTE was found by pre-cancer platelet count
above the 80th percentile ($2956109/L) compared with platelet
count below the 40th percentile (,2356109/L) both in the age-
and sex-adjusted model (HR 1.97, 95% CI 1.27–3.06) and in the
multivariable model (Model 2) (HR 1.98, 95% CI 1.21–3.23.)
Further adjustment for cancer stage (Model 3) did not change the
risk estimate (HR 1.93, 95% CI 1.18–3.16). Platelet count was not
associated with VTE in the non-cancer cohort (HR Model 2: 0.95,
95% CI 0.69–1.32), and separate analyses for provoked and
unprovoked VTE showed similar risk estimates (Table S3). When
platelet count was modeled as a continuous variable, a clear dose-
response relationship between increasing platelet count and risk of
VTE was observed in the cancer cohort, whereas no relationship
was found in the non-cancer cohort (Figure 1).
The joint effects of platelet count and leukocyte count on VTE
risk are shown in Table 4. Cancer patients in the high-high
category (platelet count $2956109/L and leukocyte count
$8.66109/L) had an age-and sex-adjusted 3-fold higher risk of
VTE (HR: 3.00, 95% CI 1.80–5.00) compared with the low-low
category (platelet count ,2956109/L and leukocyte
count,8.66109/L). In the multivariable analysis (Model 2), HR
was 3.09 (95% CI 1.80–5.32) in the upper category compared with
the lowest category. Additional adjustment for stage did not affect
the result (HR: 2.96, 95% CI1.72–5.08). A synergy index of 2.25
(calculated from the risk estimates adjusted for the variables in
Model 2) suggested a synergistic effect, and the proportion
attributable to the interaction (AP) was 38%. In the non-cancer
cohort there was no association between the various combinations
of platelet and leukocyte count and risk of VTE.
Table 2. Characteristics across categories of platelet count at the time of cancer diagnosis; The Tromsø Study 1994–2009.
Categories of platelet count (109/L) P for trend
,235 235–294 $295
Subjects, n 906 773 403
Age (years), mean 61 SD 68.1612.5 65.7612.4 63.7612.3 ,0.001
Cancer stage
Local, % (n) 36.2 (328) 33.9 (262) 29.8 (120) 0.03
Regional, % (n) 21.0 (190) 20.2 (156) 25.8 (104) 0.1
Distant metastasis, % (n) 17.8 (161) 18.0 (139) 18.9 (76) 0.7
Unknown, % (n) 25.1 (227) 27.9 (216) 26.6 (103) 0.6
Cancer site
Colon/rectum, % (n) 15.9 (144) 15.0 (116) 13.9 (56) 0.4
Prostate, % (n) 18.7 (169) 11.9 (92) 11.4 (46) ,0.001
Lung, % (n) 11.1 (101) 12.9 (100) 14.9 (60) 0.05
Breast, % (n) 11.3 (102) 13.8 (107) 12.2 (49) 0.4
Bladder and urinary tracts, % (n) 7.1 (64) 8.4 (65) 7.2 (29) 0.7
Hematopoietic/Lymphatic, % (n) 7.2 (65) 7.4 (57) 7.9 (32) 0.6
Gynecological, % (n) 6.2 (56) 7.2 (56) 7.2 (29) 0.4
Upper gastrointestinal*, % (n) 6.8 (62) 6.3 (49) 6.7 (27) 0.8
Central nervous system, % (n) 4.5 (41) 3.1 (24) 5.0 (20) 0.9
Pancreas, % (n) 4.1 (37) 2.8 (22) 2.0 (8) 0.04
All other sites, % (n) 7.2 (65) 11.0 (85) 11.7 (47) 0.003
*Includes esuphagus, stomach, small intestine, liver, gallbladder and biliary tract.
SD; standard deviation.
doi:10.1371/journal.pone.0092011.t002
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Discussion
Our population-based study is, to the best of our knowledge, the
first to identify platelet count prior to cancer development as a risk
factor for symptomatic VTE in cancer patients. Subjects with pre-
cancer platelet count above the 80th percentile ($2956109/L) had
a 2-fold increased VTE risk compared to those below the 40th
percentile (,2356109/L). The combination of platelet and
leukocyte counts in the upper quintiles had a synergistic effect
and yielded a 3-fold increased risk of VTE. In contrast, neither
high platelet count alone nor the combined effect of high platelet
and high leukocyte count did influence the risk of VTE in subjects
who remained cancer-free.
The platelet count is determined by both inherited [23,24] and
environmental factors [25]. Platelets play a central role in
hemostasis and thrombosis [6,7], but in accordance with our
findings in the non-cancer cohort, the platelet count has not been
associated with future risk of VTE in the general population [11–
13]. Conversely, a significant association between reactive
thrombocytosis and VTE has been confirmed in hospitalized
medical patients [26], intensive care unit patients [27] and trauma
patients [28,29]. There is also growing evidence that platelet count
is predictive of VTE in cancer patients. Several studies have
revealed that platelet count predicts VTE in cancer patients
treated with chemotherapy [14–16], and ambulatory cancer
patients with pre-chemotherapy platelet count $3506109/L had
Figure 1. Platelet count and risk of symptomatic venous thromboembolism. Dose-response relationship between platelet count and risk of
venous thromboembolism in cancer and non-cancer subjects obtained by generalized linear regression. The regression models are adjusted for age,
sex, body mass index, smoking, leukocyte count and mean platelet volume. The solid lines show hazard ratios and the shaded areas represent 95%
confidence intervals. Density plots show the distribution of platelet count, and white vertical lines indicate 2.5th, 25th, 50th, 75th and 97.5th percentiles.
doi:10.1371/journal.pone.0092011.g001
Table 3. Incidence rates (IRs) and hazard ratios (HRs) for symptomatic venous thromboembolism by increasing platelet count with
95% confidence intervals; The Tromsø Study 1994–2009.
Platelet count* PY{ Events IR` HR Model 1 HR Model 2 HR Model 3
Cancer
,235 4222 46 10.9 (8.2–14.5) Ref Ref Ref
235–294 3511 46 13.1 (9.8–17.5) 1.22 (0.81–1.84) 1.24 (0.80–1.90) 1.22 (0.79–1.88)
$295 1806 37 20.5 (14.8–28.3) 1.97 (1.27–3.06) 1.98 (1.21–3.23) 1.93 (1.18–3.16)
P for trend 0.004 0.008 0.01
Non-cancer
,235 120223 173 1.4 (1.2–1.7) Ref Ref -
235–294 124179 137 1.1 (0.9–1.3) 0.89 (0.71–1.11) 0.89 (0.70–1.14) -
$295 64162 67 1.0 (0.8–1.3) 0.95 (0.71–1.26) 0.95 (0.69–1.32) -
P for trend 0.5 0.6 -
*109/L.
{Person years. Subjects who develop cancer during follow-up are treated as non-cancer subjects until one year prior to the cancer diagnosis.
`Incidence per 1000 person years.
Model 1: Adjusted for age and sex.
Model 2: Adjusted for age, sex, body mass index, smoking, leukocyte count and mean platelet volume.
Model 3: Model 2+ cancer stage (defined as localized or disseminated disease).
doi:10.1371/journal.pone.0092011.t003
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a 2.8-fold increased risk of VTE [15]. Thrombocytosis prior to
cancer surgery also predicts postoperative VTE [30].
Since thrombocytosis in cancer patients may reflect the
inflammatory state associated with cancer, previous surgery or
comorbid conditions (e.g. infections), these studies are not designed
to evaluate the causality of platelet count in the development of
cancer-related VTE. In our study, the platelet counts represent
normal values in a general population, where the proportion of
subjects with recent surgery or acute medical conditions is
expected to be low. Furthermore, subjects with cancer before or
within one year after the baseline measurement were excluded,
and the participants developed cancer on average 8 years after
baseline. It is therefore reasonable to assume that the number of
individuals with platelet counts potentially influenced by occult
cancer is negligible. This is further supported by the fact that
platelet count was not associated with risk of cancer in our study.
Thus, our findings indicate that elevated platelet count, predictive
of VTE risk in cancer patients in previous studies [14–16], is not
merely an innocent bystander reflecting the malignant disease.
The VTE risk by platelet count may be mediated through high
pre-cancer values instead of the rise in platelet count due to
cancer. While high platelet counts in a general, healthy population
apparently does not increase the risk of VTE, a malignant
environment seem to convert high platelet count into a risk factor.
Alternatively, our findings may be explained by the thrombosis
potential model [31], suggesting that a high platelet count in
combination with another strong risk factor, like cancer, is
sufficient to reach the threshold for thrombosis.
Platelets promote cancer progression [8,9], and an elevated
platelet count is a common finding in cancer patients which is
associated with decreased survival [8,10]. As a consequence, pre-
cancer platelet count could represent a common underlying risk
factor for both cancer and cancer-related VTE, but in our study
we did not find pre-cancer platelet count predictive of cancer
development. Potentially, a high pre-cancer platelet count could
be associated with more aggressive cancer development, for
instance towards a more advanced cancer stage, which is a well-
known risk factor for VTE [2]. However, there were no
remarkable differences in the distribution of cancer sites across
categories of platelet count, and adjustment for disseminated
disease (regional/distant metastasis) at the time of cancer diagnosis
did not weaken pre-cancer platelet count as a risk factor for VTE
in our analyses.
The underlying mechanism by which platelet count may
contribute to VTE in cancer patients is not clear. Activated
platelets are suggested to be involved in chemotherapy-mediated
risk of VTE [32]. Both activated platelets and platelet-derived
microparticles provide a procoagulant membrane surface for the
activation of thrombin [33], which again enhances platelet-tumor
interaction and further tumor progression [34]. Thus, a high
platelet count may result in a larger membrane surface which
facilitates interaction with tumor cells and coagulation factors and
thereby promote coagulation activation.
Platelet count $3506109/L and leukocyte count $116109/L
have been recognized as risk factors for VTE in a study of 4066
cancer patients prior to chemotherapy [35]. In the present study
we demonstrated that the combination of high platelet and high
leukocyte counts had synergistic effect on VTE risk, and that 38%
of the VTE events could be attributed to the interaction. This
provides epidemiological support for a biological interaction
between platelets and leukocytes on development of VTE. A
recent experimental study on the interaction between leukocytes
and platelets in cancer-associated thrombosis further support a
mutual enhancement of prothrombotic functions [18]. In a murine
model using carcinoma mucins, the formation of platelet-rich
microthrombi was dependent on bidirectional signaling via P-
selectin on platelets and L-selectin and PSGL-1 on neutrophils.
Cathepsin G, a potent platelet agonist secreted from neutrophils,
was important in the formation of mucin-induced thrombosis [18].
P-selectin is expressed on activated platelets and interacts with
cancer cells, endothelium and leukocytes [36], and the amount of
leukocyte-platelet aggregates in the circulation is directly correlat-
ed with platelet expression of P-selectin [37]. P-selectin is also
recognized as a risk factor for cancer-related venous thrombosis
[38]. A study of VTE in mice (without cancer) found that platelet-
leukocyte interaction was dependent on the platelet receptor
GP1ba, and suggested that this interaction promoted leukocyte
recruitment and release of neutrophil extracellular traps (NETs)
Table 4. Incidence rates (IRs) and hazard ratios (HRs) for symptomatic venous thromboembolism by categories of platelet count
and leukocyte count with 95% confidence intervals; The Tromsø Study 1994–2009.
Platelet count* Leukocyte count* PY{ Events IR` HR Model 1 HR Model 2 HR Model 3
Cancer
,295 ,8.6 6513 72 11.1 (8.8–13.9) Ref Ref Ref
$8.6 1220 20 16.4 (10.6–25.4) 1.49(0.91–2.46) 1.46 (0.87–2.44) 1.45 (0.87–2.43)
$295 ,8.6 1221 18 14.7 (9.3–23.4) 1.41(0.84–2.36) 1.47 (0.86–2.51) 1.45 (0.85–2.49)
$8.6 585 19 32.5 (20.7–50.9) 3.00(1.80–5.00) 3.09 (1.80–5.32) 2.96 (1.72–5.08)
Non-cancer
,295 ,8.6 203423 272 1.3 (1.2–1.5) Ref Ref -
$8.6 40904 38 0.9 (0.7–1.3) 0.90 (0.64–1.27) 0.87 (0.61–1.24) -
$295 ,8.6 42521 41 1.0 (0.7–1.3) 0.87 (0.63–1.22) 0.89 (0.64–1.26) -
$8.6 21626 26 1.2 (0.8–1.8) 1.25 (0.84–1–88) 1.31 (0.86–1.99) -
*109/L.
{Person years. Subjects who develop cancer during follow-up are treated as non-cancer subjects until one year prior to the cancer diagnosis.
`Incidence rate per 1000 person years.
Model 1: Adjusted for age and sex.
Model 2: Adjusted for age, sex, smoking, body mass index and mean platelet volume.
Model 3: Model 2+ cancer stage (defined as localized or disseminated disease).
doi:10.1371/journal.pone.0092011.t004
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from neutrophils [7]. These mechanisms support the observed
synergistic effect of high platelet and leukocyte counts on VTE risk
in cancer patients.
The main strengths of our study are the prospective design, the
high participation rate and the well validated VTE events and
cancer diagnoses. The size of the original cohort and the long-term
follow-up made it possible to investigate VTE in cancer patients
with respect to pre-cancer exposure. Such baseline measurements
are not biased by cancer characteristics, a challenge for
interpretations in many studies. Some limitations should also be
mentioned. The cancer treatment modality was not available in
our study, and the rather limited size of the cancer cohort
restricted our possibilities to evaluate the impact of cancer sites on
the association between platelet count and risk of VTE. Moreover,
we cannot answer how platelet indices during active cancer are
related to pre-cancer measurements. The platelet count is affected
by several factors, and as in all cohort studies, unrecognized
confounding cannot be ruled out. Lastly, the platelet count in our
study was based on one single measurement. However, a review
covering 316 studies reported that the within-subject biologic
variation for platelet count is only 9.1% [39].
In conclusion, platelet count in the upper clinical range
predicted VTE-risk in patients who developed cancer during
follow-up, but not in subjects who remained cancer-free.
Additionally, the combination of high platelet and high leukocyte
counts had synergistic effect on risk of VTE in cancer patients.
Our findings suggest that platelet count and platelet-leukocyte
interactions may play a role in the pathogenesis of cancer-related
VTE.
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